2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review
Gottschalk C, Buse DC, Marmura MJ, Torphy B, Pavlovic JM, Dumas PK, Lalvani N, Blumenfeld A. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Therapeutic Advances In Neurological Disorders 2022, 15: 17562864221095902. PMID: 35662957, PMCID: PMC9160905, DOI: 10.1177/17562864221095902.Peer-Reviewed Original ResearchMigraine preventionEarly onsetDay 1Migraine daysAvailable clinical trial evidenceAnti-CGRP monoclonal antibodiesFirst treatment weekMigraine preventive therapyMigraine preventive treatmentTraditional oral agentsWeekly migraine daysClinical trial evidenceLeast moderate severityPatient-level outcomesRelevant benefitsOnset preventionOral agentsPreventive therapyChronic migraineMigraine frequencyTrial evidenceTreatment weekPreventive treatmentModerate severityPreventive benefits
2020
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.Peer-Reviewed Original ResearchConceptsEptinezumab 100Days/monthDay 1Chronic migrainePreventive efficacyCalcitonin gene-related peptideMonthly migraine daysPercentage of patientsPrevention of migraineGene-related peptideTreatment effectsMigraine preventive effectMigraine daysInitial dosePreventive effectEptinezumabWeek 1MigrainePatientsPlaceboSustained preventionMonoclonal antibodiesEfficacyMonthsNonsignificant results